CA3196264A1 - Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by farbry disease - Google Patents

Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by farbry disease

Info

Publication number
CA3196264A1
CA3196264A1 CA3196264A CA3196264A CA3196264A1 CA 3196264 A1 CA3196264 A1 CA 3196264A1 CA 3196264 A CA3196264 A CA 3196264A CA 3196264 A CA3196264 A CA 3196264A CA 3196264 A1 CA3196264 A1 CA 3196264A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
enzyme
region
fusion protein
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196264A
Other languages
English (en)
French (fr)
Inventor
Jin Young Kim
Cho Rong Park
Sang Yun Kim
Won Ki Kim
Su Yeon Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CA3196264A1 publication Critical patent/CA3196264A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3196264A 2020-11-13 2021-11-15 Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by farbry disease Pending CA3196264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200152246 2020-11-13
KR10-2020-0152246 2020-11-13
PCT/KR2021/016629 WO2022103220A1 (ko) 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도

Publications (1)

Publication Number Publication Date
CA3196264A1 true CA3196264A1 (en) 2022-05-19

Family

ID=81601490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196264A Pending CA3196264A1 (en) 2020-11-13 2021-11-15 Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by farbry disease

Country Status (12)

Country Link
US (1) US20230416714A1 (cg-RX-API-DMAC7.html)
EP (1) EP4245310A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549322A (cg-RX-API-DMAC7.html)
KR (1) KR20220065720A (cg-RX-API-DMAC7.html)
CN (1) CN116419759A (cg-RX-API-DMAC7.html)
AU (1) AU2021377712A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196264A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006516A2 (cg-RX-API-DMAC7.html)
IL (1) IL302857A (cg-RX-API-DMAC7.html)
MX (1) MX2023005579A (cg-RX-API-DMAC7.html)
WO (1) WO2022103220A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304536B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230134823A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
US11357834B2 (en) * 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
US20200157172A1 (en) * 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
EP3708661A4 (en) * 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE

Also Published As

Publication number Publication date
AU2021377712A9 (en) 2024-07-11
KR20220065720A (ko) 2022-05-20
AU2021377712A1 (en) 2023-06-01
MX2023005579A (es) 2023-05-29
CN116419759A (zh) 2023-07-11
US20230416714A1 (en) 2023-12-28
EP4245310A1 (en) 2023-09-20
IL302857A (en) 2023-07-01
JP2023549322A (ja) 2023-11-24
CO2023006516A2 (es) 2023-06-09
EP4245310A4 (en) 2024-10-30
WO2022103220A1 (ko) 2022-05-19
ZA202304536B (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US11872283B2 (en) Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US12435328B2 (en) Therapeutic enzyme fusion protein having a novel structure and use thereof
CN101321870B (zh) 在体内具有延长的半衰期和增强的红细胞生成活性的重组人EPO-Fc融合蛋白
CN110028587A (zh) 用于调节血糖和脂质的增效型双功能蛋白
IL271837B2 (en) Novel therapeutic enzyme fusion protein and use thereof
JP2011523561A (ja) Fgf21突然変異体及びその使用
AU2021377712A1 (en) Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by Fabry disease
AU2021378707A1 (en) Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by Fabry disease
JP2020528756A (ja) イズロン酸−2−スルファターゼ結合体
HK40096918A (en) Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease
EA051314B1 (ru) Применение слитого с терапевтическим ферментом белка для предупреждения и лечения нейропатии, считающейся следствием болезни фабри или ассоциированной с болезнью фабри
HK40096917A (en) Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease
CA3085252A1 (en) Dual-function protein for lipid and blood glucose regulation
CA2938366C (en) New pharmaceutical compositions and their use for the treatment of autoimmune disorders
EA051281B1 (ru) Применение слитого с терапевтическим ферментом белка для предупреждения и лечения почечного заболевания, вызванного или связанного с болезнью фабри
EA042595B1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
HK40018046A (en) Novel therapeutic enzyme fusion protein and use thereof
AU2020204470B1 (en) Dual-function protein for lipid and blood glucose regulation
HK40009561B (en) A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
EA045359B1 (ru) Новый терапевтический ферментный слитый белок и его применение

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251111

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251111

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260109

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112